Edwin Rock - Jun 20, 2024 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Chief Medical Officer
Signature
/s/ Brian F. Leaf, Attorney-in-Fact
Stock symbol
GLYC
Transactions as of
Jun 20, 2024
Transactions value $
$78,825
Form type
4
Date filed
6/24/2024, 04:29 PM
Previous filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLYC Common Stock Purchase $48.1K +190K +50.61% $0.25 565K Jun 20, 2024 Direct F1
transaction GLYC Common Stock Purchase $30.7K +115K +20.34% $0.27 680K Jun 21, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.